文献速递眼底病与葡萄膜炎

康柏西普治疗中国真实世界初治新生血管性年龄相关性黄斑变性患者

CONBERCEPT IN PATIENTS WITH TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN REAL-LIFE SETTING IN CHINA.
PubMed 文献 · Retina · 2019-01-01

本研究评估玻璃体腔注射康柏西普治疗初治新生血管性年龄相关性黄斑变性在真实世界中的疗效与安全性,采用连续3次注射后按需治疗方案。12个月随访显示最佳矫正视力从基线39.39±24.91个字母提高至44.26±22.89个字母(P < 0.001),中心视网膜厚度从480.94±178.47 μm显著降至366.33±173.52 μm,无与康柏西普相关的不良事件。

要点

  • 连续3次康柏西普注射后按需治疗,12个月视力从39.39±24.91个字母提高至44.26±22.89个字母(P < 0.001)。
  • 中心视网膜厚度从基线480.94±178.47 μm显著降至12个月时的366.33±173.52 μm。
  • 12个月时最佳反应比例为43.48%,不良反应为36.96%,无反应为19.56%。

核心结论

  • 12个月随访显示,康柏西普对真实世界初治新生血管性年龄相关性黄斑变性患者是有效且安全的治疗。

研究设计与样本

  • 本研究为真实世界研究,纳入初治新生血管性年龄相关性黄斑变性患者,给予连续3次玻璃体腔注射康柏西普后按需治疗方案。

主要发现

  • 平均最佳矫正视力从基线39.39±24.91个字母提高至末次随访44.26±22.89个字母(P < 0.001)。
  • 12个月时最佳反应比例为43.48%,不良反应比例为36.96%,无反应比例为19.56%。
  • 平均中心视网膜厚度从基线480.94±178.47 μm显著降至12个月时的366.33±173.52 μm。
  • 患者接受玻璃体腔注射的中位次数为5.32次。
  • 12个月时,伴有视网膜内囊样液的眼与不伴有视网膜内囊样液的眼相比,最佳矫正视力较基线的平均变化明显更低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In this study, we aimed to evaluate the efficacy and safety of intravitreal conbercept in patients with treatment-naive neovascular age-related macular degeneration in real-life setting. METHODS: Three consecutive intravitreal injections of conbercept following a pro re nata protocol. The main outcomes were the changes of Early Treatment Diabetic Retinopathy Study best-corrected visual acuity and central retinal thickness between the baseline and the 12th month. RESULTS: Mean best-corrected visual acuity was improved from 39.39 ± 24.91 letters at the baseline to 44.26 ± 22.89 letters at the final follow-up (P < 0.001). At the 12th month, the proportion of optimal response was 43.48% compared with 36.96% of poor response and 19.56% of nonresponse. A mean central retinal thickness of 480.94 ± 178.47 μm at the baseline was significantly reduced to 366.33 ± 173.52 μm at the 12th month. Patients received a median of 5.32 intravitreal injections. At the 12th month, the mean change in best-corrected visual acuity of eyes with intraretinal cystoid fluid from the baseline was markedly lower than that of eyes without intraretinal cystoid fluid. No adverse events were attributed to conbercept. CONCLUSION: With 12-month follow-up, conbercept was proved to be an effective and safety treatment for patients with treatment-naive neovascular age-related macular degeneration in real-life setting.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Li X, Luo H, Zuo C, et al. CONBERCEPT IN PATIENTS WITH TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN REAL-LIFE SETTING IN CHINA. Retina. 2019. PMID: 29547454. doi:10.1097/IAE.0000000000002152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。